FDA

Vion Pharmaceuticals: Onrigin application accepted but barriers remain
Vion Pharmaceuticals: Onrigin application accepted but barriers remain
Pharmaceutical Business Review
Vion Pharmaceuticals
Onrigin
FDA
leukemia
Flag link:
More FDA frustration for Discovery Labs
More FDA frustration for Discovery Labs
Bizjournals.com
FDA
Discovery Labs
Surfaxin
Flag link:
Cipla Declines on Report FDA Finds Production Flaws
Cipla Declines on Report FDA Finds Production Flaws
Bloomberg
Cipla
India
FDA
Flag link:
Recent FDA Warnings Could Signify A Shift
Recent FDA Warnings Could Signify A Shift
Investors Business Daily
FDA
Flag link:
Drugmaker Schering-Plough awaits acquisition by Merck, FDA ruling on psychiatric medicine
Drugmaker Schering-Plough awaits acquisition by Merck, FDA ruling on psychiatric medicine
Yahoo/AP
Merck
earnings
Schering Plough
buyouts
FDA
Saphris
bipolar disorder
schizophrenia
Flag link:
Biogen Idec Receives Approval for TYSABRI High Titer Production
Biogen Idec Receives Approval for TYSABRI High Titer Production
Yahoo
Biogen Idec
Tysabri
FDA
MS
multiple sclerosis
Flag link:
Botox Rival Faces Delay in FDA Marketing Approval
Botox Rival Faces Delay in FDA Marketing Approval
Bloomberg
Botox
FDA
Allergan
Medicis
Reloxin
Flag link:
Will These Drugs Get Past the FDA?
Will These Drugs Get Past the FDA?
Motley Fool
FDA
PDUFA
Savient
Medicis
Discovery Labs
Schering Plough
JNJ
Novo Nordisk
AstraZeneca
Flag link:
Updated FDA, Clinical Trial Calendars: Myriad Pharma Announces Phase 1 Trial
Updated FDA, Clinical Trial Calendars: Myriad Pharma Announces Phase 1 Trial
Seeking Alpha
FDA
drug trials
Myriad Genetics
Novartis
AstraZeneca
pSivida
Flag link:
Novartis is FDA's first priority review voucher recipient for gaining approval of a tropical disease therapy
Novartis is FDA's first priority review voucher recipient for gaining approval of a tropical disease therapy
InVivo
FDA
Novartis
malaria
review vouchers
Coartem
Flag link:
FDA Panel: Seroquel not 1st choice for depression
FDA Panel: Seroquel not 1st choice for depression
Yahoo/AP
FDA
depression
AstraZeneca
Seroquel
Flag link:
Somaxon Provides Update on New Drug Application for Silenor® (doxepin) for the Treatment of Insomnia
Somaxon Provides Update on New Drug Application for Silenor® (doxepin) for the Treatment of Insomnia
Yahoo
Somaxon
Silenor
FDA
insomnia
Flag link:
FDA panel to consider weight gain and heart risk versus benefits of Seroquel for depression
FDA panel to consider weight gain and heart risk versus benefits of Seroquel for depression
Yahoo/AP
FDA
Seroquel
AstraZeneca
depression
schizophrenia
Flag link:
FDA, Clinical Trial Calendar Updates: Alnylam Announces Phase 1 Trial
FDA, Clinical Trial Calendar Updates: Alnylam Announces Phase 1 Trial
Seeking Alpha
FDA
drug trials
Theravance
Gilead Sciences
Teva Pharmaceuticals
Alnylam
ReNeuron
Flag link:
FDA Calendar Updates: Santarus, Cephalon, AstraZeneca, Dendreon, Gilead, Novo Nordisk
FDA Calendar Updates: Santarus, Cephalon, AstraZeneca, Dendreon, Gilead, Novo Nordisk
Seeking Alpha
FDA
Santarus
Cephalon
AstraZeneca
Dendreon
Gilead Sciences
Novo Nordisk
Flag link:
FDA asks for more data on AstraZeneca's Symbicort
FDA asks for more data on AstraZeneca's Symbicort
Yahoo/AP
FDA
AstraZeneca
Symbicort
asthma
Flag link:
Rebooting the FDA
Rebooting the FDA
CNN Money
FDA
Flag link:
Bristol-Myers climbs in pre-market trade on FDA nod
Bristol-Myers climbs in pre-market trade on FDA nod
Marketwatch
FDA
Bristol-Myers Squibb
diabetes
Onglyza
AstraZeneca
Flag link:
Teva says FDA approved its generic of Bayer's Yaz birth control pill, launch planned in 2011
Teva says FDA approved its generic of Bayer's Yaz birth control pill, launch planned in 2011
Yahoo/AP
Teva Pharmaceuticals
generics
FDA
Yaz
Yasmin
birth control pill
Flag link:
FDA meeting on Bristol-Myers Squibb diabetes drug has implications for industry
FDA meeting on Bristol-Myers Squibb diabetes drug has implications for industry
Yahoo/AP
FDA
diabetes
Bristol-Myers Squibb
Onglyza
GSK
AstraZeneca
Flag link:

Pages